Placebo to match ALKS 2680
Sponsors
Alkermes Inc.
Conditions
Idiopathic Hypersomnia (IH)Narcolepsy Type 1Narcolepsy Type 2
Phase 2
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1
CompletedCTIS2024-511112-24-00
Start: 2025-01-17End: 2025-07-31Target: 117Updated: 2025-07-08
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2
CompletedCTIS2024-515452-20-00
Start: 2025-04-01End: 2025-11-11Target: 124Updated: 2026-01-13
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding
Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic
Hypersomnia
RecruitingCTIS2025-520981-23-00
Start: 2025-08-26Target: 15Updated: 2026-01-27
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Not yet recruitingCTIS2025-523911-13-00
Target: 56Updated: 2026-06-03
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Not yet recruitingCTIS2025-523912-35-00
Target: 65Updated: 2026-06-05